Loading...
menu
Search
AI Trading Bot
Features
Markets
News
Resources
Pricing
Get Started
Home
ETF
BLRX
BLRX
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
BLRX News
BioLineRx Initiates First-in-Human Trial of GLIX1 for GBM
4d ago
PRnewswire
BIOLINERX LAUNCHES PHASE 1/2A CLINICAL TRIAL OF GLIX1 FOR GLIOBLASTOMA (GBM) TREATMENT
4d ago
moomoo
BioLineRx Initiates GLIX1 Clinical Trial for Glioblastoma
Mar 23 2026
PRnewswire
BioLineRx to Initiate GLIX1 Clinical Trial for Glioblastoma
Mar 23 2026
Newsfilter
BioLineRx Reports FY EPS Beat Despite Revenue Plunge
Mar 23 2026
seekingalpha
BIOLINE RX LTD SET TO LAUNCH PHASE 1/2A CLINICAL TRIAL OF GLIX1 FOR GLIOBLASTOMA TREATMENT BY MONTH'S END
Mar 23 2026
moomoo
BioLineRx to Announce FY Earnings on March 23
Mar 20 2026
seekingalpha
BioLineRx to Release Financial Results on March 23, 2026
Mar 16 2026
PRnewswire
BioLineRx to Release Financial Results on March 23
Mar 16 2026
Newsfilter
Today's Options Volatility and Implied Earnings Changes - November 24, 2025
Nov 24 2025
TipRanks
Options Volatility and Projected Earnings Changes for the Week of November 24 – November 26, 2025
Nov 24 2025
TipRanks
BioLineRx Reports GAAP EPS of $0.00, Exceeding Expectations by $0.54; Revenue of $0.43M Falls Short by $0.24M
Nov 24 2025
SeekingAlpha
BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update
Nov 24 2025
PRnewswire
BioLineRx to Report Third Quarter 2025 Results on November 24, 2025
Nov 18 2025
PRnewswire
BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types
Nov 17 2025
PRnewswire
BioLineRx Ltd. and Hemispherian AS Establish Joint Venture to Develop GLIX1, a First-in-Class, Oral, Small Molecule Targeting DNA Damage Response in Glioblastoma and Other Cancers
Sep 29 2025
PRnewswire
Show More News
